share_log

Apollomics | 424B3: Prospectus

SEC announcement ·  Mar 5 02:56
Summary by Futu AI
Apollomics Inc., a clinical-stage biopharmaceutical company, announced on March 4, 2024, the appointment of Matthew Plunkett, Ph.D., as its new Chief Financial Officer. Dr. Plunkett brings over 25 years of experience in strategic and financial roles within the biopharmaceutical sector, including leading successful IPOs for Aeovian Pharmaceuticals and Nkarta Therapeutics. His expertise is expected to be a significant asset as Apollomics advances its clinical, regulatory, and commercialization plans, particularly for its lead drug candidates vebreltinib and uproleselan. The company, which is traded on Nasdaq under the symbols 'APLM' and 'APLMW', also filed a prospectus supplement to update information in its previous prospectus, including a press release about the new CFO appointment. Apollomics focuses on developing oncology therapies and has a pipeline of nine drug candidates, with six in clinical development. The company's securities are subject to investment risks, detailed on page 25 of the Prospectus. The last reported sale price of Apollomics' shares and warrants on March 1, 2024, was $0.76 per share and $0.03 per warrant, respectively.
Apollomics Inc., a clinical-stage biopharmaceutical company, announced on March 4, 2024, the appointment of Matthew Plunkett, Ph.D., as its new Chief Financial Officer. Dr. Plunkett brings over 25 years of experience in strategic and financial roles within the biopharmaceutical sector, including leading successful IPOs for Aeovian Pharmaceuticals and Nkarta Therapeutics. His expertise is expected to be a significant asset as Apollomics advances its clinical, regulatory, and commercialization plans, particularly for its lead drug candidates vebreltinib and uproleselan. The company, which is traded on Nasdaq under the symbols 'APLM' and 'APLMW', also filed a prospectus supplement to update information in its previous prospectus, including a press release about the new CFO appointment. Apollomics focuses on developing oncology therapies and has a pipeline of nine drug candidates, with six in clinical development. The company's securities are subject to investment risks, detailed on page 25 of the Prospectus. The last reported sale price of Apollomics' shares and warrants on March 1, 2024, was $0.76 per share and $0.03 per warrant, respectively.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.